The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-hydroxy-eicosa-5,8,11,13,17-pentaenoic acid (15-OHEPA or 15-HEPE).